1 recruiting. 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
Follow Higher Risk Myelodysplastic Syndromes: new trials by email Literature Review of Higher Risk Myelodysplastic Syndromes trials Research Report on Higher Risk Myelodysplastic Syndromes
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Bexmarilimab + Azacitidine Versus Placebo + Azacitidine in Participants With Treatment-naïve Higher-risk Myelodysplastic Syndromes bexmarilimab (1mg/kg), azacitidine, Placebo - Higher Risk Myelodysplastic Syndromes | Phase 2 | Recruiting | Faron Pharmaceuticals Ltd | 90 | 2026-10-01 | 2026-10-20 |
Neoplasms (1)
Azacitidine (1) · bexmarilimab (1)
Czechia (1) · Finland (1) · France (1) · Italy (1) · Poland (1) · United Kingdom (1) · United States (1)